Overview

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Status:
Completed
Trial end date:
2017-07-28
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if adding the combination of abiraterone acetate and prednisone with or without enzalutamide to hormonal therapy can help to control prostate cancer when given before surgery. The safety of the drug combination will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Janssen Services, LLC
Medivation, Inc.
Treatments:
Abiraterone Acetate
Hormones
Prednisone